Accretion Nutraveda IPO
Accretion Nutraveda IPO Listing Day Performance
Accretion Nutraveda listed on BSE SME on 04 February 2026 at ₹191.20, a 48.22% premium over the issue price of ₹129. A retail investor allotted the minimum application of 2,000 shares (2 lots) gained ₹1,24,400 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹60 (+46.5%) |
| GMP-implied listing | ₹189 |
| Actual listing | ₹191.20 |
| Difference | +₹2.2 (+1.2%) |
Demand going into listing
| Subscribed overall | 1.91× |
| QIB | 1.01× |
| NII | 2.42× |
| Retail | 2.19× |
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3.07 | 5.20 | 16.06 | 14.07 |
| Expense | 2.78 | 4.28 | 12.87 | 11.20 |
| Profit (PAT) | 0.28 | 0.82 | 2.61 | 2.33 |
| Total Assets | 4.06 | 4.64 | 10.86 | 16.35 |
Peer Comparison
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Walpar Nutritions Ltd. | 1.80 | 23.94 | 11 |
| Influx Healthtech Limited | 7.31 | 25.93 | 37 |
Promoters & Holding Pattern
Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 53,20,000 | 100.00% |
| Promoter Holding Post Issue | 72,40,000 | 73.48% |
Strengths & Risks
- Revenue grew 209% in the latest reported year.
- Solid profit margin — 16.3%.
- Strong return on equity — 81%.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Accretion Nutraveda at a glance
From the company's description: “Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India.”
Accretion Nutraveda is raising ₹24.77 crore through an IPO on the BSE SME in the Nutraceuticals sector. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Purchase of Machineries for New Manufacturing Setup (₹8.03 crore), Funding working capital requirements of our company (₹5.5 crore) and Purchase of Machineries for Automation in existing Manufacturing unit (₹4.22 crore).
Revenue went from ₹3.07 crore in 2023 to ₹16.06 crore in 2025, up 423% over 2 years. Profit after tax went from ₹0.28 crore to ₹2.61 crore, a net margin of 16% in the latest year.
The promoters, led by Mr. Mayur Popatlal Sojitra, hold 100% before the issue and 73% after it — a dilution of 26.5 percentage points.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Accretion Nutraveda Ltd., 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand,, Ahmedabad, Gujarat, 382213
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| Purchase of Machineries for New Manufacturing Setup | 8.03 |
| Funding working capital requirements of our company | 5.50 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Accretion Nutraveda IPO - Quick Take
Accretion Nutraveda has set a price band of Rs 122–Rs 129 per share for an issue size of Rs 25 crore in the nutraceuticals sector. The stock listed with a 48.22% gain versus its issue price on February 04, 2026.
The company operates in the nutraceuticals space.
The issue is promoted by Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel with Sobhagya Capital Options Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards purchase of Machineries for Automation in existing Manufacturing unit (Rs 4 crore) and purchase of Machineries for New Manufacturing Setup (Rs 8 crore).
On fundamentals, the company is posting revenue growth of 208.9%, a profit margin of 16.3%, return on equity of 81.2% in its most recent reported period. Listed peers in this segment include Influx Healthtech Limited (P/E 25.93x, market cap Rs 37 crore) and Walpar Nutritions Ltd. (P/E 23.94x, market cap Rs 11 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Accretion Nutraveda IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Accretion Nutraveda itself, so they describe what came before it.
- Accretion Nutraveda listed at +48.2% on day one; the median of 193 listings was +1.5% (better than 88% of them).
- Subscribed 1.91x against a median of 4.03x across 192 issues (higher than 30%).
- Average listing-day move across all 194 SME listings we track: +11.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Sobhagya Capital Options Pvt. Ltd. Lead manager | 3 0 MB · 3 SME | 33% 1 of 3 | −1.9% | −0% |
| Kfin Technologies Ltd. Registrar | 100 56 MB · 44 SME | 81% 78 of 96 | Check allotment → | |
Recent listings managed by Sobhagya Capital Options Pvt. Ltd. (3)
Best: Safety Controls +3.8% · Weakest: Paramount Syntex −9.5%
| IPO | Listed | Listing-day move |
|---|---|---|
| Paramount Syntex | 09 Oct 2026 | −9.5% |
| Quanto Agroworld | 22 Sep 2026 | −0% |
| Safety Controls | 13 Apr 2026 | +3.8% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Accretion Nutraveda IPO GMP — What It Means
Its last GMP before listing was 46.5%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Accretion Nutraveda listed 48.2% above its issue price.
See the full Accretion Nutraveda GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Accretion NutravedaNo comments yet. Be the first to share your opinion!